Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Janet Woodcock

- PMLiVE

FDA approves Bot Image’s AI software for the detection and diagnosis of prostate cancer

ProstateID combines artificial intelligence with traditional MRI scanning to significantly improve radiologic interpretation accuracy

- PMLiVE

AstraZeneca and Daiichi Sankyo get FDA approval for breast cancer drug

Results from a phase 3 trial showed Enhertu reduced the risk of disease progression or death by 50%

Bayer symbol

Bayer’s Nubeqa receives FDA approval to treat metastatic prostate cancer

The risk of death was reduced by 32% by adding the drug to standard therapy

- PMLiVE

ONS records a continued fall in UK COVID-19 infections

Latest figures have shown a drop in UK COVID-19 infections by more than half a million in a week

- PMLiVE

Eli Lilly to make bebtelovimab commercially available to US states from August

The COVID-19 antibody is expected to become commercially available prior to the anticipated depletion of the US government’s current available supply

- PMLiVE

Janssen’s Stelara approved by FDA for psoriatic arthritis in paediatric patients

Active psoriatic arthritis affects 5-8% of children and adolescents with chronic inflammatory arthritis

- PMLiVE

Arcutis receives FDA approval for steroid-free plaque psoriasis treatment

Zoryve is the first and only PDE4 inhibitor approved for plaque psoriasis

regeneron headquarters

Regeneron terminates four clinical trials of its COVID-19 antibody cocktail REGEN-COV

The drug was taken off the US market in January due to it being ‘highly unlikely’ to be active against the Omicron variant

- PMLiVE

Sarepta to submit application for Duchenne muscular dystrophy gene therapy

The condition occurs in approximately one in every 3,500-5,000 newborn males worldwide

- PMLiVE

Moderna secures £1.74bn deal to supply US government with updated COVID-19 vaccine

The company will supply 66 million doses of its COVID-19 vaccine booster updated for the Omicron subvariant

- PMLiVE

Pfizer and BioNTech initiate phase 2 study of ‘enhanced’ COVID-19 vaccine

The vaccine is based on a version of the spike protein that the companies hope will offer better and broader protection against the virus

- PMLiVE

Pfizer and BioNTech speak out against CureVac suit over patents for COVID-19 vaccines

The civil suit claims that once CureVac had withdrawn its vaccine candidate, the company was unable to garner 50% efficacy in a late-stage trial

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links